| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cucurbitacin, produced by some plants, especially Cucurbitaceae, as a defense against herbivores. Toxic compound that can form in plants in the gourd family (Zucchini, Squash). Cucurbitacins have been shown to inhibit the growth of various cancer cell lines by interfering with cell cycle progression. Cucurbitacins can affect various signaling pathways involved in cancer progression, such as the NF-κB and STAT3 pathways, which are often dysregulated in cancer. Cucurbitacin — Cucurbitacins are a family of highly oxygenated tetracyclic triterpenoids produced mainly by Cucurbitaceae plants as bitter defensive metabolites. They are best treated as a compound class rather than a single molecule; common research abbreviations include CuB, CuD, CuE, CuI, CuQ, and Cuc IIa. Their formal classification is plant-derived triterpenoid natural products with experimental cytotoxic, cytostatic, anti-inflammatory, and pathway-modulating activity. In oncology, cucurbitacin B, E, I, Q, and IIa are the most commonly studied members. Mechanistic profile dominated by ACLY↓, STAT3/JAK signaling, cytoskeletal disruption, cell-cycle arrest, apoptosis, and context-dependent chemosensitization. Primary mechanisms (ranked):
Bioavailability / PK relevance: Oral systemic translation is constrained by low solubility, low oral bioavailability, tissue distribution, narrow therapeutic window, and nonspecific toxicity. Cucurbitacin B has reported absolute oral bioavailability of approximately 10% in rat PK work, so in-vitro potency should not be assumed to translate directly to safe systemic exposure. Although CuB displays potent activity against tumor cells, its non-selective toxicity has limited its clinical applications. In-vitro vs systemic exposure relevance: Most anticancer studies use purified cucurbitacins at nanomolar to micromolar concentrations in cell lines and xenografts. Common in-vitro exposure levels may exceed reliably achievable and tolerable human systemic exposure from oral ingestion. This is a concentration-driven small-molecule class, not a field-based or device-based modality. Clinical evidence status: Preclinical. Evidence is substantial across cell-line and animal oncology models, but there is no established FDA, EMA, or Health Canada approved cucurbitacin anticancer drug. Human use is limited by toxicity concerns, lack of standardized clinical oncology dosing, and absence of robust cancer RCT evidence. Cucurbitacin Cancer Mechanism Table
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| SOD1 (superoxide dismutase 1) is a key antioxidant enzyme that catalyzes the dismutation of superoxide radicals into oxygen and hydrogen peroxide. In several cancers including breast, lung, HCC, and others, alterations in SOD1 expression have been observed, reflecting its role in managing oxidative stress. • Elevated SOD1 levels are sometimes associated with aggressive tumor behavior, therapy resistance, or decreased apoptosis due to enhanced ROS detoxification. • Conversely, the protective role of antioxidants can also mitigate oxidative mutation loads, leading to context-dependent and occasionally favorable outcomes. In non-small cell lung cancer (NSCLC), increased SOD1 levels have been reported in some cohorts, potentially as a mechanism to cope with high reactive oxygen species (ROS) levels. |
| 6185- | Cuc, | Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:195 Target#:1052 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid